Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Immune Responses in Patients Treated With Raltegravir (RAG-1/2)

This study has been terminated.
(Unexpected and severe difficulties in recruitment.)
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Chris Tsoukas, McGill University Health Center
ClinicalTrials.gov Identifier:
NCT00785967
First received: November 4, 2008
Last updated: September 27, 2011
Last verified: September 2011
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: June 2013
  Estimated Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)